Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
Open Access
- 1 February 2016
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 29 (2), 159-172
- https://doi.org/10.1016/j.ccell.2016.01.002
Abstract
• Amplified MYCN is synthetic lethal with the BCL-2 inhibitor ABT-199 in neuroblastoma • MYCN upregulates the MCL-1 inhibitor, NOXA • MYCN-amplified neuroblastomas are further sensitized to ABT-199 with MLN8237 • ABT-199 with MLN8237 induce tumor regressions in MYCN-amplified neuroblastoma miceKeywords
Funding Information
- The Rally Foundation for Childhood Cancer Research
- The Truth 365
- Alex's Lemonade Stand Innovation
- Wipe out Kids Cancer research
- VCU Massey Cancer Center Pilot Project Application
- Wellcome Trust
- George and Lavina Blick Research Fund
This publication has 62 references indexed in Scilit:
- Patient-derived models of acquired resistance can identify effective drug combinations for cancerScience, 2014
- CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven CancerCell, 2014
- Drugging MYCN through an Allosteric Transition in Aurora Kinase ACancer Cell, 2014
- CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cellsOncogene, 2013
- Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of NeuroblastomaJNCI Journal of the National Cancer Institute, 2003
- The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplificationCancer Letters, 2003
- Bcl-2 and N-Myc Coexpression Increases IGF-IR and Features of Malignant Growth in Neuroblastoma Cell LinesNeoplasia, 2001
- Targeted expression of MYCN causes neuroblastoma in transgenic miceThe EMBO Journal, 1997
- Incidence and mortality of neuroblastoma in Canada compared with other childhood cancers.Cancer Causes and Control, 1997
- Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.1991